Skip to content

Advertisement

Featured article: Circulating tumor cells as marker of poor prognosis in metastatic lung cancer

With the emergence of new diagnostic technologies in the era of personalized medicine, the search for approachable markers is hugely important. The analysis of circulating tumor cells (CTCs) and circulating tumor microemboli (CTM) may offer a minimally invasive form of monitoring treatment failure, tumor progression and recurrence. The aim of this study by Diaz et al. was to evaluate the prognostic factor of CTCs and CTM in metastatic lung cancer patients.

Articles

Most accessed articles RSS

View all articles

Submit your manuscript

Please use the online submission system to submit your manuscript to Applied Cancer Research. For all enquiries about the journal, contact: appliedcr@biomedcentral.com.

The publication costs for Applied Cancer Research are currently covered by A.C.Camargo Cancer Center and therefore no fees for article processing will be charged to authors whose articles are accepted for publication.

Archival content

Applied Cancer Research, formerly Acta Oncológica Brasileira, was founded in 1975 and transferred to BioMed Central in 2016. An electronic archive of articles published until 2015 can be found here.

Aims and scope

Applied Cancer Research is an open access, peer-reviewed journal focused on clinical, surgical and translational research in the field of oncology. The journal considers for publication original articles addressing genetics, pathology, immuno-oncology, microbiome, bioinformatics, diagnosis, treatment, patient care, and population sciences of cancer.

As a multidisciplinary journal, Applied Cancer Research aims to be a forum for exchanging relevant information among researchers, health care practitioners and health policy makers, helping them enhance prevention and decrease mortality rates from malignant diseases, improve the management of patients afflicted by them and the quality of life of people during and after treatment.

About the Editor-in-Chief

Kenneth Gollob graduated with a PhD from the University of Colorado Health Sciences Center/National Jewish Center for Immunology in 1991. His postdoctoral training was performed at DNAX Research Institute in Palo Alto, CA, and he has held positions as Visiting Associate Professor and Visiting Scientist at Stanford University School of Medicine and the Centers for Disease Control. Currently he is Head of the Translational Immuno-oncology Group at A.C. Camargo Cancer Center in São Paulo, Brazil.  His work focuses on defining immune mechanisms and biomarkers of disease progression, adverse event development, and response to standard and immunotherapy of cancer. See full Editorial Board.

Institutional affiliation


Founded in Sao Paulo in 1953, A.C.Camargo Cancer Center is an international reference center in oncology, with over 5,000 employees, in addition to 700 doctors and multidisciplinary specialists, 270 residents and 238 students enrolled in our master's and PhD courses. For more info, please visit the institution's website.

Sign up to receive article alerts

Applied Cancer Research is published continuously online-only. We encourage you to sign up to receive free email alerts to keep up to date with all of the latest articles by registering here.


Advertisement

2017 Journal Metrics

  • Speed
    47 days from submission to first decision
    143 days from submission to acceptance
    31 days from acceptance to publication

    Usage 
    29,210 Downloads
    28 Altmetric Mentions

Advertisement